🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Yongquan Shi clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Yongquan Shi as lead sponsor. Synced 26 Sep 2026
7Current trials
7Recruiting now
11Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Yongquan Shi is the lead sponsor of 7 current clinical trials in our China register. 7 are recruiting patients now. The most common phase is Phase 4. The drugs named most often in its trials are Bismuth, Tetracycline and Amoxicillin. The most-studied condition is Gastric Intestinal Metaplasia.

ClinicalTrials.gov trials by status

  • Recruiting7100%

Trials by phase

  • Phase 4571%
  • Phase 2114%
  • Observational114%
01

Clinical trials sponsored by Yongquan Shi

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment
NCT07139366 · ClinicalTrials.gov ↗ · Gastritis, Dyspepsia, Helicobacter Pylori Infection
Phase 4 Recruiting 2025-10 China
Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis(UPFRONT)
NCT07546097 · ClinicalTrials.gov ↗ · Acute Severe Ulcerative Colitis
Phase 4 Recruiting 2026-03 China
Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.
NCT06617182 · ClinicalTrials.gov ↗ · Radiation Enteritis
Phase 2 Recruiting 2024-09 China
Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial
NCT07068607 · ClinicalTrials.gov ↗ · Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer
Phase 4 Recruiting 2025-04 China
Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis
NCT07542652 · ClinicalTrials.gov ↗ · Gastric Carcinoma, Gastritis Chronic, Intestinal Metaplasia
Observational Recruiting 2026-03 China
Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia
NCT06610760 · ClinicalTrials.gov ↗ · Gastric Intestinal Metaplasia
Phase 4 Recruiting 2024-11 China
Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia
NCT06610266 · ClinicalTrials.gov ↗ · Gastric Intestinal Metaplasia
Phase 4 Recruiting 2025-02 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Yongquan Shi trials

11 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Yongquan Shi trials

12 conditions
Gastric Intestinal Metaplasia2Gastritis1Dyspepsia1Helicobacter Pylori Infection1Gastric Cancer1Acute Severe Ulcerative Colitis1Radiation Enteritis1Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer1Gastric Carcinoma1Gastritis Chronic1Intestinal Metaplasia1Gastric Precancerous Lesions1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China77

A trial with sites in more than one country appears in each of those registers.

05

Questions about Yongquan Shi trials

How many clinical trials does Yongquan Shi sponsor?

Yongquan Shi is the lead sponsor of 7 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Yongquan Shi trials recruiting?

Yes. 7 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Yongquan Shi testing?

Its current trials name 11 drugs and biologicals as interventions. The most frequent are Bismuth (2), Tetracycline (2), Amoxicillin (1), Clarithromycin (1) and Esomeprazole (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.